Medworxx
Inc. (“Medworxx”) (TSXV: MWX),
a leader in clinical utilisation review (CUR) solutions, announced that
NHS England has invited Medworxx to showcase their CUR solution at the
National Clinical Utilisation Review Showcase and Training Event on
December 11, 2014. Earlier this year the NHS England introduced a
substantial Commissioning for Quality and Innovation scheme (CQUIN) to
support providers in adopting CUR technology for specialised admitted
patient care and critical care in 2015/16. The CQUIN demonstrates NHS
England’s commitment to CUR as an essential tool to effective patient
flow within provider organisations and across local health economies and
provides NHS Hospital Trusts with set-up funding and ongoing financial
support and incentives to develop and embed recognised Clinical
Utilisation Review systems. The goal is to improve patient flow, enhance
quality and ensure patients are treated in the most appropriate clinical
settings, freeing up staff time and hospital resources.
The showcase and training event is for NHS England area teams, hospital
providers' clinicians and operational managers, and interested CCG
leaders. “The CUR event emphasizes the value placed on the application
of evidence based objective criteria in ensuring appropriate patient
care whilst identifying opportunities for whole system transformation,”
stated, Peter Ellis, Managing Director of Medworxx UK. Medworxx plans to
contribute to the National Clinical Utilisation Review event by
showcasing user experience. Acute care providers from; Annapolis Valley
Health Authority, Nova Scotia, Canada, Royal Liverpool and Broadgreen
University Hospitals NHS Trust, UK, and South Tees Hospitals NHS
Foundation Trust, UK, will speak about their experience using the
Medworxx clinical utilisation solution.
Over the last 12 months more than 20 UK hospitals and their
commissioners have used the Medworxx Clinical Utilisation Review
capability through embedded and diagnostic applications. Patient Flow
modules are used to inform patient flow improvement initiatives and to
assess whole system improvement opportunities. Medworxx is the leading
clinical utilization vendor in the UK and Canada with a combined total
of over 29,500 licensed beds using Medworxx patient flow software. “As a
clinical utilisation software provider it is gratifying to see that NHS
England recogonises the value in these offerings and has created a
risk-free environment by offering financial support to adopt CUR”, said
Dan Matlow, CEO and President, Medworxx. “Because of our success in
Canada, which also has a single payer system, we are uniquely positioned
and well matched to support a single payer based CUR strategy.”
About
Medworxx
Medworxx delivers health information technology solutions to over 350
hospitals internationally; including Canada, United States, United
Kingdom, France and Australia. Medworxx helps hospitals meet patient
flow challenges, and requirements in compliance and education. Medworxx
Clinical Criteria —flagship of Medworxx Patient Flow that includes
electronic bed management and independent assessment
components—currently serves over 34% of the acute-care beds in Canada,
and rapidly increasing number of Trusts and CCGs in the UK. Founded in
2004, Medworxx Inc. is based in Toronto, ON, and publicly traded on the
TSX Venture Exchange: MWX.
Visit: www.medworxx.com
Disclaimer
The statements made in this press release may contain forward-looking
statements that may involve a number of risks and uncertainties. Actual
events or results could differ materially from the company’s
expectations and projections. The TSX Venture Exchange has not reviewed
this press release and neither approved nor disapproved the information
contained in this press release.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20141125005095r1&sid=ntxv4&distro=nx&lang=en)
Copyright Business Wire 2014